In addition, the blockade of IGF-1R processing by small-molecule inhibition of the OST with NGI-1 suggests that tumor therapy strategies that disrupt N-linked glycosylation could potently reduce IGF-1R signaling. The gene discussed is IGF1R; the disease is neoplasm.